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Risk Stratification and Management Strategies
Introduction
Epidemiology
Dural arteriovenous malformations (DAVMs), also known as dural arteriovenous fistulas, are
arteriovenous shunts from a dural arterial supply to a dural venous channel, typically supplied by
pachymeningeal arteries and located near a major venous sinus.1 The etiology of these lesions is
not fully understood. DAVMs in the pediatric population are associated with structural venous
abnormalities ,2 but the majority of DAVMs are thought to be acquired. Different etiologies have
been implicated in this phenomenon, namely: sinus thrombosis, trauma or surgery.2–6
DAVMs have been reported in all age groups, but mainly in the fifth and sixth decades of life.7–9
The estimated incidence of DAVMs is 0.17 per 100,00010, 11 and they are one fifth as common as
arteriovenous malformations (AVMs).10, 12 They represent 10% to 15% of all intracranial vascular
malformations,10, 12–17 with a higher incidence in women. In fact, a female/male ratio of 2/1 exists in
certain anatomic sites such as the cavernous and transverse-sigmoid sinuses.6–8, 18–20 AVMs are usually
solitary, nonetheless in 5% of cases multiple lesions have been described.10, 21, 22
Natural History
DAVMs are usually acquired.6, 23 Recent experimental work suggests that the wide array of clinical
associations of DAVM may be explained by the development of venous obstruction and hypertension
with aberrant angiogenesis.24 It is hypothesized that their development arises from altered angiogenesis
within the dura following an inciting event such as trauma, surgery or chronic infection. Sinus thromboses
can be an accompanying factor in these cases. Cases have been documented of angiographically proven
dural sinus thrombosis in which DAVMs subsequently developed as a consequence of the obstructed
sinus. Next, initial microshunts proliferate in association with venous hypertension, and mature into
clinically significant arteriovenous fistulae. The degree of progression or involution determines the
significance of the abnormality. These fistulas may result in hemorrhage or other focal manifestations
including hemodynamic insufficiency. DAVMs cause decreased regional cerebral blood flow in cortical
regions where there is retrograde venous drainage.25
The development of DAVMs following trauma and surgery is well known.25, 26 They have also been
reported in association with chronic infection, vascular disease and tumors.27 Other cases of DAVM
have no clear association. They may be identified at anatomical sites distinct from the presumed
inciting event. The exact mechanism of development remains unclear. It is well established that the
development of a DAVM in these diverse settings requires a common mechanism as well as a possible
anatomic or genetic predisposition.28, 29
An established DAVM may follow one of several unpredictable natural courses. Some lesions remain
asymptomatic or maintain stable clinical symptomatology and angiographic features over many years.
Others undergo spontaneous regression, involution and resolution with stabilization or improvement
of neurological symptoms.30–35 Features that may predispose to such spontaneous involution are not
known. In fact, DAVMs in the region of the cavernous sinus are particularly prone to this phenomenon with as many as 40 percent of reported cases having undergone spontaneous involution.
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In contrast, some DAVMs may demonstrate
increase in size from either arterial or venous
enlargement 1, 12, 36 or even de novo development.37 Pachymeningeal arterial feeders may
be progressively recruited with enlargement
of the nidus. The mechanisms behind this
progressive recruitment of arterial feeders from
numerous sources have not been elucidated.
This phenomenon results in hypertrophy of
dural arteries and the reappearance of involuted
embryonic arteries that may not normally be
visible in the adult dura mater. In some DAVMs
there is also progression of pathology on the
venous side. Progressive arterialization of the
pathologic dural leaflets results in hypertension
in adjacent leptomeningeal venous channels.
This may lead to retrograde leptomeningeal
venous drainage. Under arterialized pressures
these channels may become tortuous and,
eventually, varicose or aneurysmal. The catastrophic consequence that ensues is a cerebral
hemorrhage from cortical venous drainage. In
DAVMs that present with intracranial hemorrhage and have retrograde cortical venous
drainage, there is a 35% risk of rebleeding
within the first 2 weeks. 38

Presentation
Clinical manifestations of DAVMs are highly
variable and are related primarily to the
location of the fistula as well as from the retrograde cortical venous drainage as described
above. These range from minor symptoms to
intracranial hemorrhage. The vast majority
of symptoms can be attributed to the primary
or secondary venous manifestations of the
DAVM. Presentation may be sudden or slowly
progressive. The degree and type of symptoms are determined by venous topography,
venous flow pattern and the capacity of surrounding compensatory venous drainage. As
above, the most serious neurological sequelae
from DAVMs are associated with retrograde
leptomeningeal venous drainage. 12 Focal
neurological deficits likely result from venous
hypertension and intracranial hemorrhage from
rupture of arterialized leptomeningeal veins.
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Table I: Classification of DAVMs
Type Djindjian

Cognard

Borden

I

Normal antegrade flow into dural sinus

Normal antegrade flow into dural sinus

Drains directly into venous sinus or meningeal vein

II

Drainage into venous sinus with reflux
into adjacent sinus or cortical vein

a. Retrograde flow into sinus

Drains into dural sinuses or pachymeningeal veins with retrograde drainage into
subarachnoid veins.

b. Retrograde filling of cortical veins only
c. Retrograde drainage into sinus and cortical veins
d. Drains into dural sinus or meningeal veins with
retrograde drainage into subarachnoid veins.
III

Drainage into cortical veins with
retrograde flow

Direct drainage into cortical veins with retrograde flow

IV

Drainage into venous pouch (lake)

Direct drainage into cortical veins with venous
ectasia >5mm and 3x larger than diameter of
draining vein

V
There are a wide variety of non-hemorrhagic
symptoms. 39, 40 More benign symptoms of pain,
tinnitus or bruit are related to arteriovenous
shunting and flow in the DAVM. Pulsatile
tinnitus or other subjective auditory symptoms
may occur with or without pain. These symptoms are likely related to high flow through
dural vascular channels at the base of the skull.
Other painful complaints may be related to
orbital congestion or stretching of dural leaflets
by engorged vascular channels, or to direct
compression of the trigeminal nerve by arterialized venous structures near the petrous apex.
A variety of neuro-ophthalmologic manifestations of DAVMs include visual and gaze abnormalities caused by venous hypertension, as well
as orbital or ocular venous hypertension with
resulting orbital crowding, venous stasis retinopathy and glaucoma. Other cranial DAVMs
may present with symptoms of increased intracranial pressure (ICP) or a poorly defined headache. 41, 42 While the headaches are non-specific,
there does appear to be an association with the
dysplastic changes in meningeal vessels which
are often present in DAVMs . There are also a
wide spectrum of presenting focal neurological
symptoms including seizure, hearing loss, cranial nerve palsy, papilledema and other visual
symptoms and focal motor/sensory deficits. 43–47
DAVMs may also result in altered cerebrospinal (CSF) hydrodynamics.48 Dilated venous
structures may act as mass lesions, obstructing
the CSF circulation and causing hydrocephalus. In other cases, dural venous hypertension
may result in decreased absorption of CSF
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Drains into subarachnoid veins without
dural sinus or meningeal involvement

Drainage to spinal perimedullary veins
with secondary intracranial hypertension and
papilledema. This latter complication appears
to be more common in association with high
flow lesions draining into large dural venous
sinuses and in the setting of concomitant dural
sinus outflow obstruction.
Particular clinical presentations take place with
DAVMs in specific locations. 12, 36, 39, 40 DAVMs
in the region of the transverse or sigmoid sinus,
or near the cavernous sinus, often drain into
the associated venous sinuses and may cause
a variety of clinical manifestations due to flow
or local venous engorgement. A high flow in
the region of the transverse-sigmoid sinus
junction, for example, often results in pulsatile
tinnutus, headache and bruit. This phenomenon does not lead to bleeding or cause other
deficits unless there is associated retrograde
leptomeningeal venous drainage. Lesions at the
anterior cranial fossa or the tentorial incisura
rarely drain into a patent dural venous sinus
and are more frequently associated with leptomeningeal venous drainage. They are more
likely to cause serious clinical sequelae from
venous hypertension and hemorrhage. It is
important to mention that hemorrhage has not
been reported in the absence of this feature; in
all published cases with carefully documented
diagnostic studies, hemorrhage from DAVMs
is associated with rupture of arterialized venous
structures. The prognosis of a first hemorrhage
from DAVMs is ominous, and is associated with
a greater than 30 percent mortality or serious
disability. Hemorrhage from DAVMs in anticoagulated patients has uniformly been fatal.

Classification
Location
Classification of DAVMs has evolved over time
to be useful in guiding therapeutic intervention.
Initial attempts were simplistic, emphasizing
the anatomic location (e.g., transverse-sigmoid
DAVM, cavernous DAVM, sagittal sinus
DAVM, convexity DAVM, tentorial and posterior fossa DAVM). These lacked meaningful
information in regard to predicting the nature
or outcome of the abnormality or treatment
options. Subsequent systems incorporated
information from diagnostic angiography. 5, 49, 50
Venous drainage
Perhaps one of the most well recognized
classification schemes specific to DAVMs is
that developed by Djindjian et al.49 This system
categorizes a lesion into one of four types:
type I DAVMs are characterized by normal
anterograde drainage into a venous sinus or
meningeal vein; type II lesions drain into a sinus,
with reflux into adjacent sinuses or cortical veins;
type III DAVMs drain directly into cortical veins
with resultant retrograde flow into the cerebral
venous compartment; type IV DAVMs have
drainage directly into a venous pouch (venous
lake or venous ectasia). They concluded from
their study that type I DAVMs were benign, with
each sequential type having more aggressive
characteristics. Since the introduction of the
Djindjian classification of DAVMs, other studies
have been published in the literature attempting
to correlate certain features of the DAVM with
the likelihood of associated hemorrhage or other
specific neurologic complications. 12, 39, 51, 52
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With the advent of more effective endovascular
therapeutic techniques, a means of predicting
lesion risk and management options emerged.
Cognard et al. developed a classification system
derived from a modified version of that published by Djindjian et al.50 Cognard defined
five types of DAVMs that are exclusively
based on the pattern of venous outflow. As
such, type I DAVMs were characterized by
normal antegrade flow into the affected dural
sinus. Type II lesions were associated with an
abnormal direction of venous drainage within
the affected dural sinus. These lesions could be
further categorized into three subtypes: type
IIa, lesions with retrograde flow exclusively into
the sinus or sinuses; type IIb, lesions with retrograde venous drainage into the cortical veins
only; and type IIa+b, lesions with retrograde
drainage into sinuses and cortical veins. Type
III DAVMs drained directly into a cortical vein
or veins without venous ectasia, whereas type
IV DAVMs had drainage into cortical veins
with the critical component of venous ectasia
greater than 5 mm in diameter and three times
larger than the diameter of the draining vein.
A DAVM was considered to be type V when
drainage was into spinal perimedullary veins.
Correlation with their clinical data yielded
the following conclusions: Type I DAVMs are
considered benign, and treatment is usually
not necessary, except possibly for palliation of
symptoms; type IIa lesions are best treated with
arterial embolization; while type IIb and IIa+b
lesions usually require both transarterial and
transvenous embolization for effective obliteration. For those lesions of types III through
V, transarterial and occasionally transvenous
embolization aimed at complete occlusion of
the fistula is necessary and usually will need to
be combined with surgical techniques in eradicating the threatening cortical venous drainage.
Meanwhile, Borden, et al., also proposed a classification system emphasizing venous anatomy.5
This system is appealing in its simplicity,
with only 3 categories. Type I dural AVMs
drain directly into dural venous sinuses or
pachymeningeal veins. Type II malformations
drain into dural sinuses or pachymeningeal
veins but also have retrograde drainage into
subarachnoid (leptomeningeal) veins. Type
III malformations drain solely into subarachnoid (leptomeningeal) veins and do not have
dural sinus or meningeal venous drainage.
The validity of both the Cognard and Borden
classification systems were confirmed in 102
intracranial DAVMs in 98 patients.52 (Table I)
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Risk stratification
Regardless of lesion location or previous clinical presentation or other symptomatology, the
most important factor determining the propensity of a lesion to an aggressive clinical course
appears to be the presence of leptomeningeal
venous drainage. Lesions that drain into a large
patent venous sinus may have various clinical
associations but do not bleed or cause focal
neurological deficits unless associated with
retrograde leptomeningeal venous drainage.
Lesions without drainage into a patent dural
venous sinus more frequently are associated
with leptomeningeal venous drainage and
more often are prone to more serious clinical
sequelae, such as an intracerebral hemorrhage.
As discussed, the risk of hemorrhage appears to
be related directly to the presence of tortuous
and aneurysmal leptomeningeal arterialized
veins in association with DAVMs.

Treatment
General principles of treatment
A DAVM may rarely be discovered on routine
imaging studies on digital subtraction angiography performed for other indications.
Incidental lesions must be carefully assessed
for features predisposing to aggressive clinical
behavior. Complete angiographic evaluation
is indicated in every case of suspected DAVM
unless the patient is a poor candidate for therapeutic intervention or refuses invasive diagnostic studies. Lesions should be evaluated
specifically for the presence of leptomeningeal
venous drainage and for any variceal, aneurysmal changes in the venous circulation or
venous ectasia. In the absence of these features,
the lesion should be followed expectantly. There
is no evidence to justify prophylactic treatment
of DAVMs that are not associated with leptomeningeal cortical venous drainage. Expectant
follow-up of these lesions should include serial
MR imaging for any evidence of development of
leptomeningeal venous dilations. Angiographic
re-examination of the lesion every few years
should be considered, especially for DAVMs
at the anterior cranial fossa or the tentorial
incisura, which as discussed, very commonly
harbor leptomeningeal venous drainage.
Definitive prophylactic treatment should be
strongly considered for asymptomatic and
incidentally discovered DAVMs with leptomeningeal venous drainage. The patient should
be given the option of open surgical intervention or such alternative radiosurgical or endovascular options as may be appropriate for the
specific lesion type and location. If treatment
does not succeed at totally eliminating lepto-
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meningeal venous drainage, either further
definitive therapy or very close follow-up of
the lesion is indicated. It is our belief that anticoagulation is contraindicated in the setting of
DAVMs with leptomeningeal venous drainage.
Definitive intervention for DAVMs that in
the past behaved aggressively warrants more
serious thought. Nevertheless, the morbidity of
a first hemorrhage with DAVMs is substantial,
and many patients do not survive or do not
recover to a condition suitable for therapeutic
intervention. Furthermore, little is known
about the risk either of subsequent hemorrhage
or of the progression of neurological deficits in this clinical setting. However, there are
numerous documented cases of progression of
focal neurological symptoms resulting in death
or major disability unless the DAVM is obliterated. It is our recommendation that lesions that
have hemorrhaged or that cause focal neurological symptoms due to parenchymal venous
hypotension be considered for definitive treatment. Palliative therapy is not sufficient in
this setting.
On the other hand, lesions that present with
pain or pulsatile tinnitus are evaluated and
treated in the same way as incidental lesions.
Nonspecific measures aimed at the symptoms
are usually sufficient. Palliative treatment of the
DAVM may be considered for the control of
symptomatology. Rarely is definitive treatment
indicated solely for pain or pulsatile tinnitus.
We do not believe that the risk of definitive
treatment is justified in such DAVMs as they
do not exhibit leptomeningeal venous drainage.
Lesions associated with ophthalmoplegia are
evaluated on a case-by-case basis. Frequently,
painful ophthalmoplegia will resolve spontaneously, and many such lesions involute after angiography. In other cases, ophthalmoplegia may
be progressive or associated with retinopathy
and visual loss. In such situations, treatment
of the associated DAVM is justified. Palliative
treatment may be sufficient to stabilize visual
symptoms. Again, a radical cure of the DAVM
should not be pursued at any risk, and is generally not warranted unless the symptoms are
truly debilitating or the DAVM is associated
with leptomeningeal venous drainage.
The management of DAVMs associated with
papilledema and increased intracranial pressure has been discussed previously. Palliation
or definitive cure of the DAVM frequently (but
not always) results in reversal of papilledema
and stabilization of visual symptoms. Again,
in the absence of leptomeningeal venous
drainage, the risk of radical lesion treatment
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Figure 1
This is a 46 y/o female who underwent embolization of a Right Temporo-Occipital DAVM. A) and B) Pre-embolization digital substraction angiography (DSA) images showing
multiple arterial feeders (mostly from the occipital-meningeal system). C) and D) Post-embolization DSA showing no supply from the meningeal system or occipital system after
only one embolization session.

may not be justified, and may or may not
result in subsequent control of intracranial
hypertension. Cerebrospinal fluid diversion via lumboperitoneal shunting or optic
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nerve sheath decompression may be combined with transarterial embolization and
or radiosurgery in the management of these
entities. Transvenous occlusion is rarely

possible in this setting, as it may further
compromise intracranial venous outflow.
Lumboperitoneal shunting or optic nerve
sheath decompression may effectively treat
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Figure 2
This is a 51 y/o male receiving two different embolizations for right-side DAVM. A) and B) Pre-embo DSA showing multiple ECA feeders (mostly from the occipital-meningeal
system) and cortical venous drainage (CVD). C) and D) DSA after 2 different embolizations showing persistent fistula filling and CVD. This patient subsequently needed a craniotomy
for eradication of CVD.

the secondary complications of papilledema
while the DAVM is followed expectantly,
treated palliatively, or with radiosurgery.
Ventriculoperitoneal shunting may not be

Published by Jefferson Digital Commons, 2010

possible in view of small cerebral ventricles,
and may be dangerous in the setting of arterialized cortical or subependymal veins.

In summary, clinical symptoms other than hemorrhage and progressive neurological deficits
rarely warrant radical treatment of a DAVM,
unless the lesion is particularly accessible
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or is associated with features predisposing to
subsequent aggressive clinical behavior. Patient
reassurance, symptomatic treatment, or lesion
palliation is frequently sufficient. In DAVMs
with features predisposing to an aggressive clinical course, a more definitive treatment strategy
should be adopted. It is obvious that the myriad
of clinical manifestations of DAVMs and the
wide spectrum of possible angiographic and
pathophysiologic scenarios call for highly individualized management strategies. Diagnostic
investigation should be thorough so as to
identify DAVMs with features predisposing
to aggressive clinical behavior such as leptomeningeal cortical venous drainage or venous
ecstasia. Treatment strategies should include a
highly individualized choice of modalities from
the available armamentarium of symptomatic
treatment, lesion palliation, transarterial and
/or transvenous endovascular therapy, open
surgical invention, and radiosurgery. For the
foreseeable future, the treatment of DAVMs
should preferably be entrusted to multidisciplinary teams with expertise in the recognition and management of these lesions, and
with experience in a variety of treatment
options approaches.

Direct puncture of large varices with intraoperative placement of obliteratingcoils has
been used successfully.54 A combination of
coils and glue after obtaining access by craniectomy and direct sinus puncture has also
been reported.55 Resection of the dural sinus
can be accomplished without the risk of venous
infarction if the resected segment is arterialized
and collateral channels are well developed.56
In some cases, surgical clipping of the draining vein close to the DAVM, with extensive
dural coagulation rather than resection may
be preferred.57 Recently, presigmoid skull base
exposures have been employed, specifically for
access to petrosal and sigmoid lesions.58 Image
guided frameless navigation is useful for flap
design and localization of DAVMs or associated cortical venous drainage. Intraoperative
angiography helps to ensure complete resection
in difficult cases.

Treatment strategy and location
Surgery
The goals of surgical treatment of DAVMs
include 1) physical interruption or obliteration
of arterialized leptomeningeal venous connections and 2) maximal coagulation or excision
of the pathological dura . There is a continuous
risk for significant blood loss. This is particularly
true early in the procedure when incomplete
exposure may be accompanied by significant
bleeding. From the early steps of skin infiltration and incision, the operation should proceed
in small steps, with hemostatic control before
the subsequent step. This approach is indeed
more speedy, efficient and safe than having
to take time to control brisk bleeding from
many sources. As a rule, no incision should be
made unless one was prepared to control catastrophic bleeding from it. A thorough review
of preoperative angiography and judicious
use of preoperative embolization helps to limit
this risk. Continuous communication with the
anesthesia team is critical.

Endovascular techniques
Transarterial embolization has been widely
used in the treatment of DAVMs.1, 59, 60 The
use of flow-guided catheter technology and
increased experience with particle and glue
embolization as well as detachable coils have
greatly improved the safety and efficacy of this
method.61–63 However, transarterial embolization rarely succeeds in totally eliminating and
curing a DAVM, except in rare instances of limited fistulae with a small number of accessible
feeders. More commonly, DAVMs involve a
multitude of feeders, which often arise as small
twigs from major cerebral arteries that are not
amenable to embolization. While transarterial
embolization may obliterate the filling of the
lesion after one injection, the DAVM often
continues to draw feeders from other sources,
and will reappear on subsequent angiography,
possibly in a more ominous configuration.
DAVMs that are partially treated with transarterial embolization may later recur and progress
to catastrophic hemorrhage.

Meticulous attention to hemostasis and microsurgical technique is imperative throughout
the procedure.53 Following identification,
resection of the abnormal dura is aided by the
irrigating bipolar. Small permanent vascular
clips in tandem, alternated with dural transection may be useful. Temporary aneurysm

What transarterial embolization can do is to
palliate disabling symptoms even when it does
not totally cure the DAVM. Symptom palliation may be accomplished by transarterial
embolization of external carotid artery feeders
to the DAVM, although such an intervention is
not without risk and rarely succeeds in totally
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clips are helpful in decision making prior to
coagulation and sectioning of variceal veins,
which may significantly impact adjacent cortical venous circulation. It is sometimes possible
to identify discrete arteriovenous connections
whose occlusion significantly decreases surrounding subarachnoid venous engorgement.

eliminating the DAVM. Arterial embolization
may give a false sense of security that the lesion
was “treated” while the DAVM may progress
to acquire more aggressive features including
leptomeningeal venous drainage (even in the
absence of recurrent symptoms). DAVMs that
are followed expectantly or treated palliatively
should be monitored closely with serial diagnostic studies to watch for the development of
leptomeningeal venous drainage, which may
occur without change in clinical symptoms.
Such lesions should continue to be followed
as discussed above. Transarterial embolization also plays an important role in decreasing
flow through DAVMs prior to surgical intervention, transvenous obliteration, or radiosurgery . 64–66 This adjunctive, preparatory
use of transarterial embolization has greatly
enhanced the safety and efficacy of other more
definitive treatment measures.
Noninvasive imaging methods, including MRI
and MRA may be used for interval studies,
although these modalities may miss subtle
development of leptomeningeal venous drainage, which may be clinically catastrophic.
Depending on the clinical situation and the
particular lesion, serial MR studies may be
performed on a yearly basis, with formal angiography every few years or sooner if symptoms
change, or if there is a suggestion of new leptomeningeal venous drainage on MRI .
Transvenous endovascular obliteration of
DAVMs has recently been used with good
results .67–69 This modality aims at the thrombosis of the venous side of the lesion, often
including the obliteration of the adjacent
dural venous sinus. Occlusion of the venous
side of DAVMs is usually well tolerated if
the pathologic dural sinus is arterialized and
does not serve as a site of drainage of cerebrovenous circulation. Instead, the pathologic
dural segment is often associated with harmful
retrograde leptomeningeal venous drainage,
and these channels are secondarily obliterated
with thrombosis of the venous side of DAVMs.
This strategy has been used most successfully
for the treatment of DAVMs with accessible
venous drainage. Transvenous obliteration
is particularly effective in the treatment of
cavernous sinus DAVMs (access through the
inferior petrosal sinus), although these lesions
frequently do not require any therapeutic
intervention because of their benign clinical
symptomatology and tendency toward spontaneous regression.
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Transvenous obliteration has also been used
in cases of transverse-sigmoid sinus DAVMs,
and may be substantially safer than open
surgical approaches to these lesions. However,
there may be no accessible transvenous route
for many DAVMs, including tentorial incisura DAVMs and anterior cranial fossa
DAVMs, which frequently behave aggressively.
Transvenous obliteration may occasionally
be performed after open surgical exposure,
through puncture of the dural venous sinus or
the arterialized venous varix and the injection
of coils or glue. 54 Rarely, transvenous occlusion
may result in propagating venous thrombosis
or altered hemodynamic patterns with paradoxical clinical deterioration or hemorrhage.
Occasionally, a DAVM will recur adjacent to
endovascularly occluded venous sinus, and this
could represent reconstitution of arteriovenous
channels within the walls of the occluded sinus,
or in the organized thrombus within the sinus
channel. These cases are amenable to surgical
excision of the segment of occluded sinus, and
disconnection of associated arterialized leptomeningeal veins.

The Thomas Jefferson Experience

Radiosurgery

Methods

The goal of radiosurgical treatment is sclerosis
and obliteration of arteriovenous connections within the pathological dura, resulting
in secondary thrombosis of the DAVM.
Advantages include non-invasive treatment
and avoidance of risks associated with invasive
procedures. Disadvantages include delayed
response to treatment and risk of radiation
injury to normal structures in the vicinity of
the DAVM. When combined with transarterial
embolization, 95% of patients demonstrated
symptomatic improvement and 87% demonstrated angiographic cure on angiography
performed a median of 12 months following
radiosurgery. 70 There was an acceptable
complication rate with this treatment strategy.
Radiosurgery alone was effective when the
DAVM was not amenable to embolization but
the time course for symptomatic improvement
was longer.
DAVMs of the transverse-sigmoid sinuses
treated with a similar strategy yielded a 96%
symptom resolution or significant improvement and a total or near-total obliteration
at mean angiography 21 months following
radiosurgery. 66 There were no intracerebral
hemorrhages or radiation-related complications. While the ideal treatment parameters
and ultimate role of radiosurgery continue to
evolve, it has an established role in the multimodality treatment of DAVMs.
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Background
We have amassed the longest reported followup of 39 patients who were initially treated by
endovascular means. These patients were subsequently evaluated throughout their treatment
plan in order to discern whether multi-modality
therapy would be necessary or not or whether
strict endovascular therapy would suffice. We
hereby report their outcomes and complications. Our follow-up involves patients who
were electively referred to our institution who
had a non-invasive study (such as an MRA)
illustrating the DAVM as well as those who
presented with an intracerebral hemorrhage.
The sequence of events involved a diagnostic
angiogram followed by endovascular embolization as the primary means of treatment.
Thirty-nine patients (22 males and 17 females)
underwent endovascular treatment of dural
AVMs at our primary institution from 2001–
2009. Ages ranged from 39–71 (mean age: 48).
Seventy-nine percent of patients had cortical
venous drainage.
We studied the following outcome factors:
1) the number of embolizations needed to
obliterate the lesion, and 2) the percentage of
patients requiring transvenous embolization,
craniotomy, or radiosurgery for eradication of
the lesion after endovascular management.
We also inspected whether those patients who
were initially found to have retrograde cortical
venous drainage had subsequent eradication of
this phenomenon after multi-modality therapy.
Finally, we assessed post operative complications from either of the modalities.
Results
Outcomes toward Obliteration
of Fistulous Component

The number of endovascular embolizations
performed in order to decide on whether
to proceed with surgery, radiosurgery or
ascertain complete obliteration of the fistulas was 2.1. This was an average obtained
by adding up the number of endovascular
embolizations needed to obtain at least a
95% reduction in fistula flow in all patients
studied. We deemed the DAVM as “treated”
when this result was obtained as per the
observation of the angiographer. Seventyone percent (71%) (28/39) of patients had
complete obliteration of the fistula; 21 of
those by endovascular means and 7 via craniotomy. Figure 1 illustrates eradication of the
DAVM after one embolization session.

Neurovascular

Of the eleven patients who did not have complete obliteration of the fistula, seven of those
(64%) had at least 90% obliteration with only
one feeding pedicle remaining. Three patients
needed radiosurgery as a final approach for
treatment. The average dose utilized for eradication of the DAVM was 22 Gy in single fraction.
Outcomes Toward Eradication of Retrograde Cortical
Venous Drainage

We studied whether retrograde cortical venous
drainage would be eradicated by various
components of multi-modality therapy. 87%
(26/30) of patients had full obliteration of their
cortical venous drainage. Of these 26 patients,
69% (18/26) had obliteration obtained by endovascular means while the rest needed surgical
venous ligation. Figure 2 illustrates treatment
of a patient by multi-modality therapy to eradicate both the cortical venous drainage phenomenon as well as the fistulous component.
It is interesting to note that in five of these 18
patients who had CVD treated endovascularly,
success was only obtained when a transvenous
approach was performed.
Complications

The following complications were noticed:
epidural infection after craniotomy (1), post op
intracranial hemorrhage not requiring surgery
after embolization (1), and need for vein patch
procedure after uncontrolled femoral bleeding
(1). All above complications were diagnosed
and treated expeditiously.
Analysis

Endovascular treatment of DAVMs is a safe
and effective way to treat these complex
lesions. Additional modalities such as surgery
and radiosurgery have become adjuvant in the
treatment of these lesions. We strongly believe
based on this data that endovascular embolization should be the primary modality for treating
DAVMs.
Prognosis and outcome
An established DAVM has an unpredictable
natural course, varying from spontaneous
regression to more venous recruitment and
hemorrhage, depending on the presence or
absence of leptomeningeal venous drainage.
The prognosis of a first hemorrhage from
DAVMs is ominous, and has been shown to be
associated with greater than 30% mortality or
serious disability. The annual bleeding risk of a
DAVM varies between 1.8 to 15% ,71 the risk of
rebleed over the period of two weeks has been
estimated to be around 35%.38 The acute or
gradual progression from one grade to the next
has been described.

JHN JOURNAL

7

11

JHN Journal, Vol. 5 [2010], Iss. 2, Art. 2

Any change in the bruit or symptoms of a
DAVM should warrant reevaluation to rule out
the development of alternative drainage paths
such as leptomeningeal drainage pathways.
Recently carotid duplex sonography has been
reported as a tool for follow up of treated dural
AVMs, with a correlation of the resistance
index of the external carotid artery with the
effectivness of treatment.72
Conclusion
Much has been learned in recent years about
the pathoanatomy, pathophysiology, natural
history and therapeutic options for DAVMs.
A better understanding of these lesions has
allowed more prompt and precise diagnosis,
and a realistic assessment of features predisposing to aggressive clinical course. Treatment
is not only guided toward the palliation of
clinical symptoms, but as importantly, toward
prevention of future sequelae. The therapeutic
armamentarium includes a number of options
with varying risk and effectiveness for individual
lesions. Transarterial embolization, transvenous
embolization, surgical therapy or radiosurgery
can be used alone or in various combinations as
required for individual clinical scenarios.
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At Jefferson Hospital for
Neuroscience, neurologist Michael
M. Moussouttas, MD, and nurse
Lauren Dougherty use the Jefferson
Expert Teleconsulting (JET) system to
consult with Robert H. Rosenwasser,
MD, FACS, Chair, Department of
Neurological Surgery (pictured on
monitor), who is at another location.

Pioneering Leading-Edge Treatments
Jefferson Hospital for Neuroscience staff have helped to
develop and/or have introduced to the region leadingedge treatments and technologies that reduce the need
for open brain surgery for stroke, brain aneurysms and
AVMs. Among them:
• Intra-arterial thrombolysis with tPA – pharmacological
blood clot-dissolving
• Mechanical thrombectomy devices – e.g., Merci
Retrieval System®
• Wingspan stent – FDA-approved mesh tube to open
blocked arteries in the brain after clot-dissolving drugs
have failed
• Coiling, gluing and stenting of brain aneurysms –
reduces need for open brain surgery

Announcing Jefferson’s Teleconsulting (JET) Robotic System for Help with
Diagnosis and Treatment of Time-Sensitive Neurovascular Diseases
“Time is brain” is the credo among healthcare
professionals for diagnosing and treating timesensitive neurovascular diseases, including arteriovenous malformations (AVMs), brain aneurysms and,
especially, stroke. The blood-clot busting medication
tissue plasminogen activator (tPA), for example, must
be administered to a patient having a stroke within
4.5 hours for best chance of functional recovery.
Timely performance of neurosurgical procedures
to remove AVMs and aneurysms are similarly
urgent. Yet many community hospitals have limited
experienced staff and technology to diagnose and
treat patients quickly and accurately.
Now, to provide sophisticated care and expertise
to patients at hospital emergency rooms in small
community hospitals in distant areas of eastern
Pennsylvania, south and central New Jersey, and
Delaware, Jefferson Hospital for Neuroscience
(JHN) in Philadelphia is launching Jefferson Expert
Teleconsulting (JET), the region’s first university-based
high-tech mobile robotic system for neuroscience.
“JET places all of our resources – among them, dualtrained neurosurgeons, advanced technology, and
leading-edge clinical trials in which we partner with the
National Institutes of Health – at the disposal of patients,
their families and physicians in need of a second, expert
opinion,” says Robert H. Rosenwasser, MD, FACS,
Professor and Chair, Department of Neurological
Surgery, JHN and Jefferson Medical College of Thomas
Jefferson University. “Its greatest value is for timely
diagnosis and application of treatment for time-sensitive
neurovascular diseases, especially stroke.”
Enhancing level of care
“We want to partner with hospitals in other
communities to help advance stroke care throughout

the region. As the leading provider of stroke care
in the region, we have an obligation to do that,”
adds Pamela Kolb, Vice President, Neuroscience
Service, JHN.
Supported by Thomas Jefferson University, a
leading academic center, JHN is the region’s only
dedicated hospital for neuroscience and leading,
most experienced and comprehensive center for
diagnosis and treatment of stroke and cerebrovascular
disease. JHN’s Acute Stroke Center is the largest such
facility, with more board-certified neurocritical care
physicians than most, in the greater Delaware Valley.
It is also a Joint Commission-accredited primary
stroke center.
“Stroke is the third-leading cause of death in the
United States but the leading cause of disability, by a
factor of five over any other disease,” Dr. Rosenwasser
notes. “Given its prevalence and time-sensitive nature,
it is alarming how few people receive treatment in the
appropriate amount of time. With JET, even hospitals
in remote areas can provide patients with expert
consultation and disposition of appropriate care from
an experienced neurologist or neurological surgeon
immediately in cases where every minute can make a
critical difference. It’s a very cost-effective approach to
providing 24/7 onsite coverage and expertise.”
How JET works
Each participating hospital is supplied with a mobile
robotic platform, manufactured by InTouch Health®
of Santa Barbara, CA, that enables the JHN Network
physician to be remotely present. JET’s panoramic
visualization system and easy-to-use control interface
afford physicians, patients and hospital staff a safe and
effective interactive experience.

InTouch’s remote presence devices are the first and
only with FDA approval. The robots allow direct
connection to medical devices such as electronic
stethoscopes, otoscopes and ultrasound to transmit
medical data to the remote physician.
“Should a patient arrive in the ER of a hospital that’s
located, say, three hours away from Jefferson and
either doesn’t have a neurologist or neurosurgeon
available or has a neurologist who needs to consult
with a neurosurgeon,” Dr. Rosenwasser, explains, “the
attending physician contacts JHN. The JHN Network
specialist on call then uses a laptop to connect to
the remote hospital via the robot, obtain a medical
history by speaking directly with the patient and/or
family members, examine the patient and determine
what therapy is immediately needed, in real time,
without delay. Finally, a decision is made either to
admit the patient to the local hospital’s Critical Care
Unit or transfer him or her to the Jefferson Acute
Stroke Center, by JeffSTAT, Jefferson’s transport
service, or the hospital’s own service.”
“Patients may not need to be transferred – they can
stay in their own community and be treated very
successfully there, thanks to this program,” says Ms.
Kolb. “And most patients want to stay close to home.
JET enables them to receive sophisticated medical
care without having to travel long distances.”
“It also serves as an educational program,” adds Dr.
Rosenwasser. “As a teaching center, JHN will use
JET to share our clinical protocols with participating
hospitals so that they can enhance stroke care within
their communities. On the other hand, should the
patient need an advanced neurosurgical procedure
[See sidebar], we can arrange for prompt transfer.”

JHN continues to set the standard worldwide
for state-of-the-art care for time-sensitive
neurovascular diseases. For more information
about these and other treatments, visit
www.JeffersonHospital.org/neuroscience.
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